Emulgel-Based Formulations of Clobetasol Propionate: Formulation Development, Characterization, and Pharmacological Evaluation.

Q2 Pharmacology, Toxicology and Pharmaceutics

Pharmaceutical nanotechnology Pub Date : 2025-02-20 DOI:10.2174/0122117385327270241224080729

Kuldeep Singh, Jeetendra Kumar Gupta, Divya Jain, Mukesh Chandra Sharma, Shivendra Kumar, Ramkumar Chaudhary, Sakshi Mishra

{"title":"Emulgel-Based Formulations of Clobetasol Propionate: Formulation Development, Characterization, and Pharmacological Evaluation.","authors":"Kuldeep Singh, Jeetendra Kumar Gupta, Divya Jain, Mukesh Chandra Sharma, Shivendra Kumar, Ramkumar Chaudhary, Sakshi Mishra","doi":"10.2174/0122117385327270241224080729","DOIUrl":null,"url":null,"abstract":"<p><p>Topical formulations of corticosteroids, particularly clobetasol propionate (CP), are commonly used to treat a range of dermatological conditions. CP is a potent corticosteroid known for its efficacy in managing inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Emulgel-based formulations of CP have emerged as an innovative approach, offering advantages like improved drug solubility, enhanced skin penetration, and extended drug release. This review aims to provide an updated overview of the latest advancements in the development and evaluation of CP emulgel formulations. Key aspects discussed include the selection and optimization of emulgel components, formulation characterization, in vitro drug release, and pharmacological activities such as anti-inflammatory and anti-pruritic effects. Emphasis is placed on recent studies and innovations that underscore the potential of CP emulgels in dermatological therapy, highlighting their promising applications in enhancing therapeutic efficacy and patient outcomes.</p>","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385327270241224080729","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Topical formulations of corticosteroids, particularly clobetasol propionate (CP), are commonly used to treat a range of dermatological conditions. CP is a potent corticosteroid known for its efficacy in managing inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Emulgel-based formulations of CP have emerged as an innovative approach, offering advantages like improved drug solubility, enhanced skin penetration, and extended drug release. This review aims to provide an updated overview of the latest advancements in the development and evaluation of CP emulgel formulations. Key aspects discussed include the selection and optimization of emulgel components, formulation characterization, in vitro drug release, and pharmacological activities such as anti-inflammatory and anti-pruritic effects. Emphasis is placed on recent studies and innovations that underscore the potential of CP emulgels in dermatological therapy, highlighting their promising applications in enhancing therapeutic efficacy and patient outcomes.

查看原文本刊更多论文

皮质类固醇的外用制剂，尤其是丙酸氯倍他索（CP），常用于治疗一系列皮肤病。氯倍他索丙酸酯是一种强效皮质类固醇，在治疗皮质类固醇反应性皮肤病的炎症和瘙痒表现方面疗效显著。基于 Emulgel 的氯化石蜡制剂已成为一种创新方法，具有改善药物溶解度、增强皮肤渗透性和延长药物释放时间等优点。本综述旨在概述在开发和评估氯化石蜡凝胶制剂方面取得的最新进展。讨论的主要方面包括乳凝胶成分的选择和优化、配方表征、体外药物释放以及药理活性（如抗炎和止痒作用）。重点放在最近的研究和创新上，这些研究和创新强调了氯化石蜡凝胶在皮肤病治疗中的潜力，突出了其在提高疗效和患者预后方面的应用前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmaceutical nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.20

自引率

0.00%

发文量

期刊介绍： Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.